Share on StockTwits

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) were the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 14,527,055 shares, a growth of 10.8% from the April 15th total of 13,111,252 shares, American Banking and Market News reports. Based on an average daily volume of 2,141,032 shares, the days-to-cover ratio is currently 6.8 days. Currently, 14.9% of the company’s stock are short sold.

In other ACADIA Pharmaceuticals news, Director Torsten Rasmussen sold 32,857 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $20.03, for a total transaction of $658,125.71. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on ACAD shares. Analysts at Jefferies Group raised their price target on shares of ACADIA Pharmaceuticals from $26.00 to $38.00 in a research note on Tuesday, March 4th. Analysts at Zacks downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. ACADIA Pharmaceuticals has an average rating of “Buy” and an average target price of $26.33.

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) opened at 18.87 on Thursday. ACADIA Pharmaceuticals has a one year low of $12.72 and a one year high of $32.00. The stock’s 50-day moving average is $20.45 and its 200-day moving average is $23.43. The company’s market cap is $1.868 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.06. Analysts expect that ACADIA Pharmaceuticals will post $-0.81 EPS for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.